All In Biotech

Drug Trial Radar · NCT07417449

Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP

The Impact of Long-Term Dutasteride Use on Surgical Outcomes and Perioperative Parameters in Patients Undergoing Holmium Laser Enucleation of the Prostate (HoLEP)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

Nov 30, 2026

Study completion Jan 1, 2027

Sponsor

Lead sponsor
Ankara City Hospital BilkentAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 18, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Male only, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to investigate the effects of long-term dutasteride use (a 5-alpha reductase inhibitor) on surgical outcomes in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for benign prostatic hyperplasia (BPH). While some studies suggest that short-term use of these medications can reduce bleeding during surgery, there is limited data on the impact of chronic, long-term use (at least 6 months) specifically during the HoLEP procedure. The researchers will retrospectively analyze patient records to compare two groups: those who used dutasteride for 6 months or longer before surgery, and those who did not use any 5-alpha reductase inhibitors. The primary focus is to determine whether long-term dutasteride treatment leads to a significant difference in surgical bleeding (measured by hemoglobin drop), operation time, and the efficiency of removing prostate tissue (morcellation). The findings will help surgeons better understand how preoperative medication history influences the technical aspects of HoLEP surgery.

Conditions

  • Prostatic Hyperplasia, Benign

Interventions

  • DutasterideDrug

    Patients in the study group received 0.5 mg/day of dutasteride for at least 6 months before surgery as part of their routine BPH treatment.

  • Holmium Laser Enucleation of the Prostate (HoLEP)Procedure

    Standard HoLEP procedure performed for the surgical treatment of benign prostatic hyperplasia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hemoglobin Levels (Hemoglobin Drop)Time frame: From the time of hospital admission (preoperative) up to 24 hours after surgery.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ankara Bilkent City Hospital

    Ankara, Universiteler, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.